Hutchison China MediTech Receita T/T
Qual é o Receita T/T de Hutchison China MediTech?
O Receita T/T de Hutchison China MediTech Ltd. é -42.64%
Qual é a definição de Receita T/T?
O crescimento trimestral da receita, ano após ano, é o aumento da receita de uma empresa em comparação com o desempenho no trimestre correspondente do ano anterior, expresso como uma porcentagem.
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
Receita T/T de empresas na Setor Health Care em LSE em comparação com Hutchison China MediTech
O que Hutchison China MediTech faz?
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Empresas com receita t/t semelhantes a Hutchison China MediTech
- Venzee Technologies tem Receita T/T de -42.73%
- Stereotaxis tem Receita T/T de -42.72%
- Riba Textiles tem Receita T/T de -42.69%
- Bega Cheese tem Receita T/T de -42.68%
- Nagreeka Exports tem Receita T/T de -42.67%
- Bowl America tem Receita T/T de -42.67%
- Hutchison China MediTech tem Receita T/T de -42.64%
- Startek tem Receita T/T de -42.61%
- Integrated Diagnostics plc tem Receita T/T de -42.57%
- iSentric tem Receita T/T de -42.50%
- Skyline tem Receita T/T de -42.50%
- 51 Credit Card tem Receita T/T de -42.44%
- Broo tem Receita T/T de -42.42%